Pfizer

Pfizer Inc.(PFE) – Historic performance of revenue and earnings

in , , on March 30, 2023

This report is useful for M&A and business & investment analysis to all students, researchers, investors, private equity houses, broking firms, hedge funds, advisory firms and corporates to decide upon their investment strategies. Do connect with us, if you are looking for insights on any specific sector/industry and market recommendations.

Pfizer Inc. (PFE) Q4FY22

PEE has been strategically investing in growth opportunities which can enhance the long term product offerings to its customers.

Highlights

Valuation

– Enterprise Value
– CrispIdea Forecast
– CrispIdea Segment Forecast
– Economic Value Added Analysis
– Discounted Cash Flow Analysis
– P/E Analysis
– Peer Valuation
– CrispIdea Forecast Relative to Consensus
– Consensus History and Surprise
– Consensus Momentum

Actual & Historical Performance

– Income Statement
– Balance Sheet
– Cash Flow
– 10 Year Historical Performance
– Ratio Analysis
– Du Pont Analysis
– ROIC & ROCE Analysis
– Segment Performance
– Key Developments
– M&A Deals

Peer Performance

– Summary
– Profitability
– Growth
– Price Performance

Ownership

Stock Price Performance of Pfizer Inc

Crispidea Coverage

No of Pages: 36

To view the previous quarter’s report click here

Follow our LinkedIn page for more updates

Release Information

  • Price
    :

    $99.00

  • Released
    :

    March 30, 2023

  • Last Updated
    :

    March 30, 2023